FXN

Across TCGA pan-cancer cohorts, FXN mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FXN data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FXN mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated FXN expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, GBM, and COAD are the cancer types where FXN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.728	0.234	.007	17	view →
GBM	OS	Tertile	All	0.702	0.401	.014	12	view →
COAD	DFS	Tertile	II,III,IV	1.000	0.914	.044	6	view →
HNSC	OS	Median	II,III,IV	0.952	1.000	.016	6	view →
CCRCC	DFS	Median	II,III,IV	1.000	0.542	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FXN–PDAC (OS)

Open the PDAC breakdown →